The prognostic value of LVI in breast cancer has been extensively studied and the majority of studies have considered LVI as a marker of increased risk of axillary nodal metastases and unfavorable survival outcome in all breast phenotypes except in the HER2-positive subgroup (30). This evidence concerns the gene ERBB2 and breast cancer.